|Title of host publication||Reference module in biomedical sciences|
|Publication status||Published - 2016|
Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.